N@N

Reni Benjamin Reiterated (BPMC) at Buy and Held Target at $114 on, Aug 7th, 2023

Reni Benjamin of JMP Securities, Reiterated "Blueprint Medicines Corporation" (BPMC) at Buy and Held Target at $114 on, Aug 7th, 2023.

Reni has made no other calls on BPMC in the last 4 months.

There are 9 other peers that have a rating on BPMC. Out of the 9 peers that are also analyzing BPMC, 2 agree with Reni's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $59 on, Thursday, August 3rd, 2023
• Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $46 on, Tuesday, May 23rd, 2023

These are the ratings of the 7 analyists that currently disagree with Reni

---

• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $85 on, Thursday, August 3rd, 2023
• Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $65 on, Thursday, August 3rd, 2023
• Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $83 on, Thursday, August 3rd, 2023
• Derek Archila of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $83 on, Monday, July 31st, 2023
• Andrew Berens of "SVB Leerink" Downgraded from Hold to Sell and Decreased Target to $43 on, Monday, June 5th, 2023
• Liana Moussatos of "Wedbush" Reiterated at Buy and Held Target at $75 on, Tuesday, May 23rd, 2023
• Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $82 on, Tuesday, May 23rd, 2023

Contributing Sources

---